ReviewCancers2026
Integrating Artificial Intelligence into Breast Cancer Histopathology: Toward Improved Diagnosis and Prognosis.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Histopathological evaluation of tissue sections remains the gold standard for the diagnosis, classification, and grading of breast cancer (BC). The widespread adoption of whole-slide imaging (WSI) has enabled the digitization of histological slides and facilitated the development of artificial intelligence (AI) approaches for computational pathology. In recent years, machine learning and deep learning (DL) algorithms have been increasingly investigated for the analysis of hematoxylin and eosin (H&E)-stained images, with potential applications in tumor detection, histological classification, prognostic stratification, and prediction of treatment response. This narrative review summarizes recent developments in AI-driven models applied to BC histopathology and discusses their potential role in supporting diagnostic and prognostic assessment. Several studies have demonstrated the promising performance of DL algorithms in tasks such as the detection of lymph node metastases, assessment of residual tumor after neoadjuvant therapy, and prediction of clinical outcomes from histopathological images. Emerging research has also explored the possibility of inferring molecular and biomarker information from histology images, although these approaches currently identify statistical associations rather than direct molecular measurements. Despite the rapid expansion of this research field, significant barriers remain before routine clinical implementation can be achieved. Key challenges include dataset bias, variability in staining and image acquisition, limited external validation across institutions, and the need for transparent and reproducible model development. In addition, the translation of AI-based systems into clinical practice requires compliance with regulatory frameworks governing software used for medical purposes, such as those established by the U.S. Food and Drug Administration. Overall, AI represents a promising research direction in computational pathology and may contribute to decision-support tools capable of assisting pathologists in the analysis of digital slides. Continued efforts toward methodological rigor, large multicenter datasets, and prospective validation studies will be essential to determine the future role of AI in BC histopathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.